Christopher K. Mutz

Christopher K. Mutz

Senior Vice President, Head of Rare DiseaseatAni Pharmaceuticals· In proxies 2021–2025

Pay in FY2025+40% from the year before · Ani Pharmaceuticals stock +42.8% the same year

Christopher K. Mutz was paid $3.4M in FY2025 (Dec), up 40%. Ani Pharmaceuticals stock rose 42.8% that year.

Pay$100 in the stock at the end of FY20 → $272
Pay is from the Summary Compensation Table of each Ani Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Ani PharmaceuticalsPublic company · 5 yr
    • Senior Vice President, Head of Rare Disease2021 – Present · 5 yrStock in role +156%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?